- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 27.11. | The new era of medical affairs: busting myths and supercharging strategic value | ||
| 26.11. | J&J's Tremfya improves symptoms of psoriatic arthritis including joint damage | ||
| 26.11. | Novartis announces plans for new US manufacturing hub | ||
| 25.11. | The most overlooked KPI in business? Joy | ||
| 25.11. | Reimagining pharma CX: three game-changing products driving human-centric innovation | ||
| 25.11. | When populism meets public health: trust under siege | ||
| 25.11. | The building of Aspire Pharma and values | ||
| 25.11. | Merck KGaA given FDA Fast Track designation for generalised myasthenia gravis drug | ||
| 25.11. | Major prostate cancer screening trial launched in UK | ||
| 24.11. | Pfizer's PADCEV gets FDA approval for bladder cancer | ||
| 24.11. | AstraZeneca announces $2bn investment in US manufacturing | ||
| 21.11. | Novartis reports primary endpoint reached in phase 3 malaria trial | ||
| 21.11. | Merck agrees deal with Cidara Therapeutics worth almost $9.2bn | ||
| 20.11. | PMEA 2025: a celebration of excellence in pharmaceutical marketing | ||
| 20.11. | J&J receives positive NICE recommendation for multiple myeloma treatment | ||
| 20.11. | VML Portugal appoints Managing Director | ||
| 20.11. | Younger, not invisible: rewriting cancer care - starting with the pancreas | ||
| 19.11. | Biogen and Eisai receive MHRA approval for updated dosing of early Alzheimer's treatment | ||
| 19.11. | Gilead reports Trodelvy breast cancer trial missed primary survival endpoint | ||
| 18.11. | Novo Nordisk reports phase 3 data showing semaglutide reduces liver scarring | ||
| 18.11. | InflaRx reports positive phase 2 results for HS and CSU treatments | ||
| 17.11. | Amgen reports positive results from landmark cardiovascular study | ||
| 17.11. | AstraZeneca reports positive results from rare disease trial | ||
| 14.11. | Scientists uncover new drug target in fight against antimicrobial resistance | ||
| 14.11. | Merck ends development agreement with Dr Falk Pharma for monoclonal antibody |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .